Increased health costs from mandated Therapeutic Substitution of proton pump inhibitors in BC.

Download Full Article Article Brief


Authors: Dr. Brett J Skinner, Ph.D.; Dr. James R Gray, M.D.; Gail P Attara, Canadian Society of Intestinal Research

In 2003, British Columbia’s PharmaCare programme implemented a drug reimbursement policy called Therapeutic Substitution, which required patients with acid-related diseases, primarily gastro-oesophageal reflux disease (GERD), to make a medically unnecessary switch from their prescribed proton pump inhibitor (PPI) to the cheapest available brand name PPI (Pariet, rabeprazole sodium), comprising a different (nongeneric) chemical. This study evaluates the independent effects of PPI Therapeutic Substitution on individual healthcare utilization among those complying with the policy.

By permission from Blackwell Publishing Limited, the publisher of Alimentary Pharmacology & Therapeutics, an article summary is republished here (modified for CHP format) and the original document is also posted here for free download. A web link to the original article is provided here at URL:

Subscribe image

CHP blogazine